Immunohistochemical study of colorectal polyps with antibodies against CEA, CA19-9, CA125, CA15-3 (DF3), PCNA and p53

Digestive Endoscopy

Volumn 8, Issue 2, 1996, Pages 93-100

  Saito, K ^a   Ogawa, A ^a   Ohki, I ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

CA125; CA15 3 (DF3); CA19 9; CEA; Colorectal polyp; p53; PCNA

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; POLYCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER;

ADENOMA; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; COLON POLYP; COLORECTAL TUMOR; CONTROLLED STUDY; ETIOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; RECTUM POLYP;

EID: 0029984685     PISSN: 09155635     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-1661.1996.tb00422.x     Document Type: Article

References (44)

1. 1 Morson BC. Precancerous and early malignant lesions of the large intestine. Br J Surg 1968 ; 55: 926–31.
2. 2 Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987 ; 328: 614–6.
3. 3 Leppert M, Dobbs M, Scambler P et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987 ; 238: 1411–13.
4. 4 Law DJ, Olschwang S, Monpezat J et al. Concerted nonsynthetic allelic loss in human colorectal carcinoma. Science 1988 ; 241: 961–5.
5. 5 Vogelstein B, Fearon ER, Hamilton MR et al. Genetic alterations during colorectal‐tumor development. N Engl J Med 1988 ; 319: 1138–46.
6. 6 Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989 ; 244: 217–21.
7. 7 Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990 ; 247: 49–56.
8. 8 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990 ; 61: 759–67.
9. 9 Gold P, Freedman SO. Demonstration of tumor‐specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965 ; 121: 439–63.
10. 10 Koprowski H, Steplewski Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetic 1979 ; 5: 957–72.
11. 11 O'Brien MJ, Zamcheck N, Burke B et al. Immunocyto‐chemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Am J Clin Pathol 1981 ; 75: 283–90.
12. 12 Jothy S, Brazinsky SA, Chin‐A‐Loy M et al. Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity. Lab Invest 1986 ; 54: 108–17.
13. 13 Wiggers T, Arends JW, Verstijnen C et al. Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue. Br J Cancer 1986 ; 54: 409–14.
14. 14 Afdhal NH, Long A, Tobbial et al. Immunohistochemical CA19‐9 in primary colonic polyps and polyps synchronous with colorectal cancer. Gut 1987 ; 28: 594–600.
15. 15 McKenzie KJ, Purnell DM, Shamsuddin AM. Expression of carcinoembryonic antigen, T‐antigen, and oncogene products as markers of neoplastic and preneoplastic colonic mucosa. Hum Pathol 1987 ; 18: 1282–6.
16. 16 Van den Ingh HF, Bara J, Cornelisse CJ et al. Aneuploidy and expression of gastric‐associated mucous antigens Ml and CEA in colorectal adenomas. Am J Clin Pathol 1987 ; 87: 174–9.
17. 17 Enblad P, Busch C, Carlsson U et al. The adenoma‐carcinoma sequence in rectal adenomas. Am J Clin Pathol 1988 ; 89: 121–30.
18. 18 Higashide T, Hinoda Y, Itoh J et al. Detection of mRNA of carcinoembryonic and nonspecific cross reacting antigen genes in colorectal adenomas and carcinomas by in situ hybridization. Jpn J Cancer Res 1990 ; 81: 1149–54.
19. 19 Taguchi T, Kijima H, Mitomi T et al. Immunohistochemical study of colorectal adenocarcinomas and adenomas with antibodies against carcinoembryonic antigen (CEA), CA19‐9, keratin, α ‐tubulin and secretory component. Gastroenterol Jpn 1991 ; 26: 294–302.
20. 20 Bast RC, Feeney M, Lazarus H et al. Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981 ; 68: 1331–7.
21. 21 Marechal F, Berthiot G, Kortley T, Legrand MG. Analysis of CA‐125 level in sera of patients with non‐ovarian carcinomas and non‐malignant disease. Anticancer Res 1989 ; 9: 593–8.
22. 22 Kufe DW, Inghirami G, Abe M et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984 ; 3: 223–31.
23. 23 Hilkens J, Buiis F, Hilgers J et al. Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984 ; 34: 197–206.
24. 24 Sekine H, Ohno T, Kufe DW. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985 ; 135: 3610–15.
25. 25 Ohtani H, Nagura H, Ohuchi N. Immunoelectron microscopic localization of DF3 cancer associated antigen in human breast cancer. Pathol Res Pract 1991 ; 187: 1014–19.
26. 26 Friedman EL, Hayes DF, Kufe DW. Reactivity of monoclonal antibody DF3 with high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res 1986 ; 46: 5189–94.
27. 27 Kamoshida S, Shirai M, Kasuya M et al. Comparative immunohistochemical localization of CA15‐3 (DF3 antigen) and CA19‐9 in cancerous and noncancerous tissues: Pathology and Clinical Medicine. Tokyo: Bun-koudou Publishing Company 1993 ; 11: 1073–9. (in Japanese).
28. 28 Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978 ; 121: 2228–34.
29. 29 Mathews MB, Bernstein RM, Franza BR, Garrels JL. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984 ; 309: 374–6.
30. 30 Bravo R, Flank R, Blundell PA, MacDonald‐Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase‐δ. Nature 1987 ; 326: 515–17.
31. 31 Prelich G, Tan C, Kostura M et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase‐δ auxiliary protein. Nature 1987 ; 326: 517–20.
32. 32 Celis JE, Celis A. Cell cycle‐dependent variations in the distribution of the nuclear protein cyclin/proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci USA 1985 ; 82: 3262–6.
33. 33 Hall PA, Levision DA, Woods AL et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990 ; 162: 285–94.
34. 34 Takasaki Y, Deng JS, Tan EM. A nuclear antigen associated with cell proliferation and blast formation. J Exp Med 1981 ; 154: 1899–909.
35. 35 Robbins BA, Vega D, Ogata K, et al. Immunohistological detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987 ; 111: 841–5.
36. 36 Garcia RL, Coltrera MD, Grown AM. Analysis of proliferative grade using anti‐PCNA/cyclin monoclonal antibodies in fixed embedded tissue. Am J Pathol 1989 ; 134: 733–9.
37. 37 Tomita T. DNA ploidy and proliferating cell nuclear antigen in colonic adenoma and adenocarcinoma. Dig Dis Sci 1995 ; 40: 996–1004.
38. 38 Tanaka S, Harumura K, Tatsuta S et al. Proliferating cell nuclear antigen expression correlates with the metastatic potential of submucosal invasive colorectal carcinoma. Oncology 1995 ; 52: 134–9.
39. 39 Levine AJ. Tumor suppressor genes. Bioessays 1990 ; 12: 60–6.
40. 40 Yamaguchi A, Kurosawa Y, Fushida S et al. Expression of p53 protein in colorectal cancer and its relationship to short‐term prognosis. Cancer 1992 ; 70: 2778–84.
41. 41 Pignatelli M, Stamp GWH, Karifi G et al. Overexpres‐sion of p53 nuclear oncoprotein in colorectal adenoma. Int J Cancer 1992 ; 50: 683–8.
42. 42 Yukawa M, Fujimori T, Nagasako K et al. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumors. Gut 1994 ; 35: 1258–61.
43. 43 Rodrigues NR, Rowan A, Smith MEF et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990 ; 87: 7555–9.
44. 44 Kudo S, Hirota S, Nakajima T et al. Colorectal tumors and pit pattern. J Clin Pathol 1994 ; 47: 880–5.